Komori
Business Alliances4563AnGes,Inc.Pharmaceuticals

Initiatives to Enhance Corporate Value through a Business Partnership with グロースパートナーズ

Anges has entered into a business partnership with グロースパートナーズ株式会社 and stated that it will strengthen its domestic and international licensing activities and alliances, as well as overseas business development, by leveraging the partner’s expertise and network in management support and business development support.

Worth reading
35Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Agreements reached under this partnership

Business Alliances
4563AnGes,Inc.
Alliance partnerName of alliance partner
Details of the alliance
  1. 1

    Strengthening domestic and international licensing and business partnership activities

  2. 2

    Exploring new alliance opportunities

  3. 3

    Considering measures to optimize the business portfolio

  4. 4

    Promoting business development activities with a view to overseas markets

  5. 5

    Strengthening IR activities and initiatives to enhance corporate value

These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.

About the partner
Business DescriptionHands-on services providing financing, management support, business development support, M&A support, DX promotion and various alliance support to operating companies
Impact on Business Performance

The aim is to enhance corporate value over the medium to long term.

Contract Date14 August 2026Alliance start dateAlready launched. Specific start date: Not disclosed
Agreements reached under this partnership
ItemDetails
Name of alliance partnerName of alliance partner
Alliance partner's business activitiesHands-on services providing financing, management support, business development support, M&A support, DX promotion and various alliance support to operating companies
Type of allianceBusiness Alliances
Details of the allianceStrengthening domestic and international licensing and business partnership activities, Exploring new alliance opportunities, Considering measures to optimize the business portfolio, Promoting business development activities with a view to overseas markets, Strengthening IR activities and initiatives to enhance corporate value
Contract Date14 August 2026
Alliance start dateAlready launched. Specific start date: Not disclosed
Impact on Business PerformanceThe aim is to enhance corporate value over the medium to long term.
Items this document does not state (16)
Alliance partner's locationAlliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionShare Acquisition Date and Payment DateChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To maximize the value of its technology assets, business platform and development pipeline relating to gene therapeutics, it is important to strengthen domestic and international business partnerships and licensing activities, business development functions and marketing functions. The company therefore determined that cooperation with external partners was necessary to expand its business in overseas markets.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Initiatives to Enhance Corporate Value through a Business Partnership with グロースパートナーズ | AnGes,Inc. (4563) timely disclosure | Komori